Market Cap 11.34B
Revenue (ttm) 0.00
Net Income (ttm) -380.27M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 886,023
Avg Vol 2,329,390
Day's Range N/A - N/A
Shares Out 79.77M
Stochastic %K 85%
Beta 0.87
Analysts Strong Sell
Price Target $157.42

Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Industry: Biotechnology
Sector: Healthcare
Phone: 33 1 53 83 09 63
Address:
7-11 Boulevard Haussmann, Paris, France
StreetwiseReports
StreetwiseReports Jul. 9 at 7:33 PM
French Clinical-Stage Biotech's UC Drug Faces 'Best in Disease' Doubts as Analyst Lifts Target Ahead of 4Q26 FDA Filing https://ow.ly/4neC50ZmaMi A Wedbush analyst raised its target on a French biopharma's ulcerative colitis candidate but disputed bullish efficacy claims, flagging Jak competition and a 2027 Crohn's readout. $ABVX
0 · Reply
thesharkinthedark
thesharkinthedark Jul. 9 at 7:09 PM
$ABVX this is going to 230$ if u like it or not Everything that could be bearish, is now the past 1. The offering was OVERSUBSCRIBED 4-5 times 2. Cancer cases were Nonesense 3. Company has a massive pipeline and if they run by themselves what they currently have is already worth around 165-170$ 4. In an article, they have confirmed that they are in talks with a few few big pharmas Don’t miss it. Just chill. Let them work. $XBI $ABVX $QQQ $CRNX
0 · Reply
TimothyMancha548
TimothyMancha548 Jul. 9 at 4:37 PM
$ABVX Piper’s upgrade leans on a recent gastroenterologist KOL survey and the view that malignancy concerns are basically off the table now. Also worth noting: Piper had been book-running manager on the recent capital raise, so the bullish tone isn’t exactly a surprise.
0 · Reply
BullNavigatorr
BullNavigatorr Jul. 9 at 4:17 PM
$ABVX Piper lifted 2035 UC revenue from $3.7B to $4.2B. $CRNX just got bought for $10B on est. peak rev of $4.2B ($VRTX had a $4.5B proj). $ABVX sits at a $12.2B market cap. Either $CRNX was taken 20% below fair value or $ABVX is trading about 20% rich.
2 · Reply
Quantumup
Quantumup Jul. 9 at 2:51 PM
Piper Sandler⬆️ $ABVX's PT to $175 from $165,⬆️U.S. 2035 UC revenue est to $4.2B, reiterated Overweight and said -- Updating Model, Raising UC Estimates; Continue to See Upside CRVS $SYRE PTGX - JNJ APGE - $ABBV PALI RHHBY MRK TEVA Here's what else Piper Sandler had to say: https://x.com/Quantumup1/status/2075231157604478978?s=20
0 · Reply
thesharkinthedark
thesharkinthedark Jul. 9 at 1:52 PM
$ABVX Piper Sandler raised their price target for $ABVX from 165$ to 175$ This is not including a buyout scenario $XBI
0 · Reply
jackbones
jackbones Jul. 9 at 12:56 PM
$ABVX piper increased target just now from $165 to $175, that’s without buyout premium
0 · Reply
H4ck7
H4ck7 Jul. 9 at 12:43 PM
$ABVX You don’t even have to scroll for more than 15 seconds to find all your shit @TheCaretaker TRASHHHHHHH
0 · Reply
H4ck7
H4ck7 Jul. 9 at 12:42 PM
$ABVX @TheCaretaker Dude you fucking trash hahahhahahaahhaha
0 · Reply
Machiaveltrade
Machiaveltrade Jul. 9 at 10:28 AM
$ABVX Agree with you, BO very soon
0 · Reply
Latest News on ABVX
Abivax price target raised to $175 from $165 at Piper Sandler

2026-07-09T11:21:30.000Z - 10 hours ago

Abivax price target raised to $175 from $165 at Piper Sandler


Abivax: Wall Street Catches Up to the Data

Tue, 07 Jul 2026 12:25:55 -0400 - 2 days ago

Abivax: Wall Street Catches Up to the Data


Abivax Announces Closing of $920 Million Public Offering

Mon, 06 Jul 2026 16:05:00 -0400 - 3 days ago

Abivax Announces Closing of $920 Million Public Offering


Abivax price target raised to $155 from $135 at Truist

2026-07-02T11:15:43.000Z - 7 days ago

Abivax price target raised to $155 from $135 at Truist


Abivax (ABVX) Raises $800M in Upsized Public Offering

2026-07-01T14:57:34.000Z - 8 days ago

Abivax (ABVX) Raises $800M in Upsized Public Offering


ABIVAX Announces Pricing Of $800 Mln Offering Of ADS

2026-07-01T12:58:05.000Z - 8 days ago

ABIVAX Announces Pricing Of $800 Mln Offering Of ADS


Abivax announces $600M ADS offering

2026-06-30T20:50:18.000Z - 9 days ago

Abivax announces $600M ADS offering


Abivax upgraded to Buy from Hold at Jefferies

2026-06-30T20:10:14.000Z - 9 days ago

Abivax upgraded to Buy from Hold at Jefferies


Abivax (ABVX) Shares Surge Over 35% Amid Market Movements

2026-06-30T17:31:26.000Z - 9 days ago

Abivax (ABVX) Shares Surge Over 35% Amid Market Movements


Abivax rises 35.8%

2026-06-30T16:00:15.000Z - 9 days ago

Abivax rises 35.8%


Abivax (ABVX) Sees Significant Share Price Surge

2026-06-30T15:30:11.000Z - 9 days ago

Abivax (ABVX) Sees Significant Share Price Surge


Abivax rises 37.8%

2026-06-30T14:00:15.000Z - 9 days ago

Abivax rises 37.8%


Abivax (ABVX) Surges 33.6% Ahead of Market Open

2026-06-30T12:58:22.000Z - 9 days ago

Abivax (ABVX) Surges 33.6% Ahead of Market Open


Abivax price target raised to $110 from $90 at Wedbush

2026-06-30T11:50:38.000Z - 9 days ago

Abivax price target raised to $110 from $90 at Wedbush


Abivax price target raised to $175 from $150 at BTIG

2026-06-30T11:25:31.000Z - 9 days ago

Abivax price target raised to $175 from $150 at BTIG


Abivax (ABVX) Shares Surge 27% on Positive Phase 3 Results

2026-06-30T09:56:59.000Z - 9 days ago

Abivax (ABVX) Shares Surge 27% on Positive Phase 3 Results


Abivax trading resumes

2026-06-29T21:05:19.000Z - 10 days ago

Abivax trading resumes


ABIVAX Société Anonyme Transcript: Study result

Jun 29, 2026, 4:30 PM EDT - 10 days ago

ABIVAX Société Anonyme Transcript: Study result


ABIVAX Société Anonyme Press release: Study result

Jun 29, 2026, 4:30 PM EDT - 10 days ago

ABIVAX Société Anonyme Press release: Study result


ABIVAX Société Anonyme Slides: Study result

Jun 29, 2026, 4:30 PM EDT - 10 days ago

ABIVAX Société Anonyme Slides: Study result


Abivax announces results from ABTECT Maintenance Part 2

2026-06-29T20:20:27.000Z - 10 days ago

Abivax announces results from ABTECT Maintenance Part 2


Abivax trading halted, news pending

2026-06-29T20:05:29.000Z - 10 days ago

Abivax trading halted, news pending


This Is Why Abivax Stock (ABVX) Is Up Today

2026-06-03T18:41:24.000Z - 5 weeks ago

This Is Why Abivax Stock (ABVX) Is Up Today


ABIVAX Société Anonyme Transcript: Study result

Jun 1, 2026, 4:30 PM EDT - 5 weeks ago

ABIVAX Société Anonyme Transcript: Study result


ABIVAX Société Anonyme Press release: Study result

Jun 1, 2026, 4:30 PM EDT - 5 weeks ago

ABIVAX Société Anonyme Press release: Study result


ABIVAX Société Anonyme Slides: Study result

Jun 1, 2026, 4:30 PM EDT - 5 weeks ago

ABIVAX Société Anonyme Slides: Study result


ABIVAX Société Anonyme Earnings release: Q1 2026

May 22, 2026, 11:40 AM EDT - 6 weeks ago

ABIVAX Société Anonyme Earnings release: Q1 2026


ABIVAX Société Anonyme Earnings release: Q1 2026

May 22, 2026, 11:40 AM EDT - 6 weeks ago

ABIVAX Société Anonyme Earnings release: Q1 2026


Abivax to Present Data on Obefazimod at Digestive Disease Week®

Apr 22, 2026, 4:05 PM EDT - 2 months ago

Abivax to Present Data on Obefazimod at Digestive Disease Week®


ABIVAX Société Anonyme Annual report: Q4 2025

Mar 23, 2026, 12:45 PM EDT - 3 months ago

ABIVAX Société Anonyme Annual report: Q4 2025


ABIVAX Société Anonyme Earnings release: Q4 2025

Mar 23, 2026, 12:45 PM EDT - 3 months ago

ABIVAX Société Anonyme Earnings release: Q4 2025


Abivax CEO dismisses 'noise' around rumored Eli Lilly bid

Jan 20, 2026, 6:01 AM EST - 6 months ago

Abivax CEO dismisses 'noise' around rumored Eli Lilly bid

LLY


Abivax stock rockets 30% on Eli Lilly takeover speculation

Jan 12, 2026, 9:32 AM EST - 6 months ago

Abivax stock rockets 30% on Eli Lilly takeover speculation

LLY


Abivax shares soar 23% as media report reignites M&A chatter

Jan 12, 2026, 4:38 AM EST - 6 months ago

Abivax shares soar 23% as media report reignites M&A chatter

LLY


Abivax Provides 2026 Corporate Outlook

Jan 7, 2026, 4:05 PM EST - 6 months ago

Abivax Provides 2026 Corporate Outlook


Abivax to be Added to Nasdaq Biotechnology Index

Dec 18, 2025, 4:05 PM EST - 7 months ago

Abivax to be Added to Nasdaq Biotechnology Index


ABIVAX Société Anonyme Earnings release: Q3 2025

Dec 15, 2025, 11:45 AM EST - 7 months ago

ABIVAX Société Anonyme Earnings release: Q3 2025


French biotech Abivax's shares climb on Eli Lilly bid rumors

Dec 10, 2025, 5:52 AM EST - 7 months ago

French biotech Abivax's shares climb on Eli Lilly bid rumors

LLY


ABIVAX Société Anonyme Press release: FY 2025

Oct 6, 2025, 9:00 AM EDT - 9 months ago

ABIVAX Société Anonyme Press release: FY 2025


ABIVAX Société Anonyme Slides: FY 2025

Oct 6, 2025, 9:00 AM EDT - 9 months ago

ABIVAX Société Anonyme Slides: FY 2025


Abivax Presents First Half 2025 Financial Results

Sep 8, 2025, 4:00 PM EDT - 10 months ago

Abivax Presents First Half 2025 Financial Results


ABIVAX Société Anonyme Quarterly report: Q2 2025

Sep 8, 2025, 11:45 AM EDT - 10 months ago

ABIVAX Société Anonyme Quarterly report: Q2 2025


ABIVAX Société Anonyme Earnings release: Q2 2025

Sep 8, 2025, 11:45 AM EDT - 10 months ago

ABIVAX Société Anonyme Earnings release: Q2 2025


How Hedge Funds Won Big on an Obscure Drugmaker

Aug 30, 2025, 5:30 AM EDT - 11 months ago

How Hedge Funds Won Big on an Obscure Drugmaker


Abivax Announces Closing of $747.5 Million Public Offering

Jul 28, 2025, 4:15 PM EDT - 1 year ago

Abivax Announces Closing of $747.5 Million Public Offering


Abivax Announces Launch of Public Offering

Jul 23, 2025, 4:15 PM EDT - 1 year ago

Abivax Announces Launch of Public Offering


ABIVAX Société Anonyme Transcript: Study Result

Jul 22, 2025, 4:30 PM EDT - 1 year ago

ABIVAX Société Anonyme Transcript: Study Result


ABIVAX Société Anonyme Press release: Study Result

Jul 22, 2025, 4:30 PM EDT - 1 year ago

ABIVAX Société Anonyme Press release: Study Result


ABIVAX Société Anonyme Slides: Study Result

Jul 22, 2025, 4:30 PM EDT - 1 year ago

ABIVAX Société Anonyme Slides: Study Result


StreetwiseReports
StreetwiseReports Jul. 9 at 7:33 PM
French Clinical-Stage Biotech's UC Drug Faces 'Best in Disease' Doubts as Analyst Lifts Target Ahead of 4Q26 FDA Filing https://ow.ly/4neC50ZmaMi A Wedbush analyst raised its target on a French biopharma's ulcerative colitis candidate but disputed bullish efficacy claims, flagging Jak competition and a 2027 Crohn's readout. $ABVX
0 · Reply
thesharkinthedark
thesharkinthedark Jul. 9 at 7:09 PM
$ABVX this is going to 230$ if u like it or not Everything that could be bearish, is now the past 1. The offering was OVERSUBSCRIBED 4-5 times 2. Cancer cases were Nonesense 3. Company has a massive pipeline and if they run by themselves what they currently have is already worth around 165-170$ 4. In an article, they have confirmed that they are in talks with a few few big pharmas Don’t miss it. Just chill. Let them work. $XBI $ABVX $QQQ $CRNX
0 · Reply
TimothyMancha548
TimothyMancha548 Jul. 9 at 4:37 PM
$ABVX Piper’s upgrade leans on a recent gastroenterologist KOL survey and the view that malignancy concerns are basically off the table now. Also worth noting: Piper had been book-running manager on the recent capital raise, so the bullish tone isn’t exactly a surprise.
0 · Reply
BullNavigatorr
BullNavigatorr Jul. 9 at 4:17 PM
$ABVX Piper lifted 2035 UC revenue from $3.7B to $4.2B. $CRNX just got bought for $10B on est. peak rev of $4.2B ($VRTX had a $4.5B proj). $ABVX sits at a $12.2B market cap. Either $CRNX was taken 20% below fair value or $ABVX is trading about 20% rich.
2 · Reply
Quantumup
Quantumup Jul. 9 at 2:51 PM
Piper Sandler⬆️ $ABVX's PT to $175 from $165,⬆️U.S. 2035 UC revenue est to $4.2B, reiterated Overweight and said -- Updating Model, Raising UC Estimates; Continue to See Upside CRVS $SYRE PTGX - JNJ APGE - $ABBV PALI RHHBY MRK TEVA Here's what else Piper Sandler had to say: https://x.com/Quantumup1/status/2075231157604478978?s=20
0 · Reply
thesharkinthedark
thesharkinthedark Jul. 9 at 1:52 PM
$ABVX Piper Sandler raised their price target for $ABVX from 165$ to 175$ This is not including a buyout scenario $XBI
0 · Reply
jackbones
jackbones Jul. 9 at 12:56 PM
$ABVX piper increased target just now from $165 to $175, that’s without buyout premium
0 · Reply
H4ck7
H4ck7 Jul. 9 at 12:43 PM
$ABVX You don’t even have to scroll for more than 15 seconds to find all your shit @TheCaretaker TRASHHHHHHH
0 · Reply
H4ck7
H4ck7 Jul. 9 at 12:42 PM
$ABVX @TheCaretaker Dude you fucking trash hahahhahahaahhaha
0 · Reply
Machiaveltrade
Machiaveltrade Jul. 9 at 10:28 AM
$ABVX Agree with you, BO very soon
0 · Reply
BioRich
BioRich Jul. 9 at 7:52 AM
$DRTS This post should get us trending. Love this darling coming from the outside and charging for the lead in the sector. Expect a lot of $SLS cashouts to roll to $DRTS. $IBRX $ABVX and $KYTX also. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
2 · Reply
Pinhus
Pinhus Jul. 9 at 2:12 AM
$ABVX $ABVX Two days ago at $144, I said the stock would drop $5–10. It did and keeps dropping in after hours… And the bagholders who purchased it at $145+ attacked me with insults like a bunch of hyenas. Well, they vanished the moment the chart proved them wrong. Now they sit quiet, pretending they never talked tough, still unaware of the part that matters: This isn’t a dip — it’s a drift toward the offering price at $125, exactly where the real weight of the move sits. The crowd hated the call. The tape confirmed it. And the silence says the rest.
4 · Reply
p3akyblinder
p3akyblinder Jul. 8 at 8:35 PM
$MLTX The massive gap on the 1-year chart is going to fill this summer IMHO. This set up looks exactly like the huge gap $ABVX had before the redemption arc. Excited...
3 · Reply
StreetwiseReports
StreetwiseReports Jul. 8 at 7:59 PM
Abivax SA (ABVX) UC Opportunity: Oral Therapy Catalyst https://ow.ly/YP7p50ZlNAi Abivax SA ( $ABVX ) advances obefazimod through Phase 3 success in ulcerative colitis with NDA filing targeted for late 2026. Learn why this oral miR-124 therapy stands out for investors now.
0 · Reply
traderjoe90
traderjoe90 Jul. 8 at 7:48 PM
$ABVX pain trade is lower for now. No one selling. Dealers looking for shares.
0 · Reply
KS202525
KS202525 Jul. 8 at 7:46 PM
$ABVX Nothing to say.
0 · Reply
jm0olah
jm0olah Jul. 8 at 7:43 PM
$ABVX rebacking up the truck sub 130
0 · Reply
StreetwiseReports
StreetwiseReports Jul. 8 at 5:51 PM
How Do Analysts Rate This Biotech Focused on Chronic Inflammatory Diseases? https://ow.ly/fMVQ50ZlJEN Find out what analysts think of clinical-stage biotech Abivax SA ( $ABVX ), which is focusing on harnessing the immune response in patients with chronic inflammatory diseases.
0 · Reply
Pinhus
Pinhus Jul. 8 at 3:52 PM
$ABVX Look at this downside 😘 My prediction was right on!
2 · Reply
ButcherBillCutting
ButcherBillCutting Jul. 8 at 3:18 PM
$ABVX Could you imagine they slow drip this down to the offering price of $125? Offering participants have a 60day lock So I would be careful around there. However, open gap 128-110 roughly To be filled? 200D ma at around $113? I’m just saying. 😂😂
1 · Reply
Pinhus
Pinhus Jul. 8 at 2:21 PM
$ABVX I will be covering in the low $130’s for a close to ~ $8000 profit! 🤓
0 · Reply
Machiaveltrade
Machiaveltrade Jul. 8 at 12:58 PM
$ABVX so many scaring bears here…funny!
1 · Reply